z-logo
Premium
The stereospecificity of LY253352 for α 1 ‐adrenoceptor binding sites in the brain and prostate
Author(s) -
Lepor Herbert,
Baumann Mary,
Shapiro Ellen
Publication year - 1988
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1988.tb16557.x
Subject(s) - dissociation constant , radioligand , enantiomer , human brain , chemistry , stereospecificity , prostate , adenoma , endocrinology , antagonist , alpha (finance) , receptor , medicine , stereochemistry , biology , neuroscience , biochemistry , patient satisfaction , construct validity , cancer , catalysis , nursing
1 The stereospecificity of the enantiomers of LY253352, a potent and selective α 1 ‐adrenoceptor antagonist, were studied in the human prostate and canine brain using radioligand receptor binding methods. 2 The mean equilibrium dissociation constant ( K D ) in the canine brain and human prostatic adenoma was 84.4 pM and 65.4 pM, respectively. 3 The α 1 ‐adrenoceptor density in the canine brain was approximately eight fold greater than in the human prostatic adenoma. 4 The mean K i values of (−)‐LY253352 and (+)‐LY253352 in the prostate were 0.19 nM and 5.79 nM, respectively. 5 The mean K i values of (−)‐LY253352 and (+)‐LY253352 in the brain were 0.29 nM and 34.7 nM, respectively. 6 This study indicates that the stereochemical specificity of the optical isomers of LY253352 is a manifestation of differential affinities of the enantiomers for α 1 ‐adrenoceptor binding sites. 7 The differential affinities of (+)‐LY253352 in the brain and prostate are suggestive of subtle unique properties of adrenoceptor binding sites in these tissues.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here